



Immuron Expands Collaboration with US Navy to Collaborate on Campylobacter and ETEC

Melbourne, Australia, August 30, 2016: Australian microbiome biopharmaceutical company Immuron Limited (ASX: IMC), is pleased to announce that the Company has executed a Research and Development Collaboration Agreement for the testing of Travelan in cell lines of Campylobacter and Enterotoxigenic Escherichia coli (ETEC) with the Naval Medical Research Center (NMRC).

Campylobacter and ETEC are gram-negative bacteria and are major causes of Traveler's Diarrhea in both developed and developing countries especially in Thailand and surrounding areas of Southeast Asia. In a study of American military personnel deployed in Thailand, more than half of those with diarrhea were found to be infected with *Campylobacter* species:

- Campylobacteriosis is an infectious disease caused by bacteria of the genus *Campylobacter*. In most people who become ill with campylobacteriosis, symptoms develop within two to five days of exposure to the organism and illness typically lasts seven days following onset. At least a dozen species of *Campylobacter* have been implicated in the human disease, with *Campylobacter jejuni* being the most common. *Campylobacter jejuni* is in a genus of bacteria that is among the most common causes of bacterial infections in humans worldwide. Infection with *C. jejuni* usually results in enteritis, which is characterised by abdominal pain, diarrhea, fever, and malaise. Diarrhea itself can vary in severity from loose to bloody stools.
- *Campylobacter* organisms have a large animal reservoir, with up to 100% of poultry, including chickens, turkeys, and waterfowl, having asymptomatic intestinal infections. Contaminated drinking water, unpasteurized milk and contaminated food is a major source of isolated infections, with incorrectly prepared meat and poultry as the primary source of the bacteria.
- *C. jejuni* is now recognised as one of the main causes of bacterial foodborne disease in many developed countries, as well as developing countries where poultry is common.
- Enterotoxigenic Escherichia coli (ETEC) is a type of Escherichia coli (E-coli) and is one of the leading bacterial causes of diarrhea in the developing world, as well as the most common cause of travelers' diarrhea. Conservative estimates suggest that each year, about 157,000 deaths occur, mostly in children, from ETEC, but no vaccines exist, highlighting the need for new treatment modalities.

NMRC is a major research laboratory within the US Navy. Its research and mission focuses on eliminating infectious disease agents and on infectious disease vaccine development, operational and undersea medicine, bone marrow research and biological warfare.

Similar to our current collaboration agreement with the US Army / Walter Reed Army Institute of Research (WRAIR), the long-term goal of this collaboration is to develop therapeutics that can be utilised for both commercial and government use. Clinical trials conducted under an Investigational New Drug application (IND) with the US Food and Drug Administration (FDA) would open the door for the potential approval of *campylobacter* and *ETEC* vaccine-based products that meet the needs of both military personnel and civilian populations.

Based on the results of the testing with the US Army and the US Navy, it might also be possible to develop a vaccine-based hyperimmune colostrum product that contains all three sets of antibodies, providing a truly broad-spectrum prescription product for both military and civilian use.

Thomas Liquard, CEO of Immuron commented;

“This is our second collaboration with the US DoD signed in quick succession. This highlights the importance that the anti-infectives specialists at the US DoD place on the potential of Immuron’s technology. We are extremely proud of entering into this collaboration agreement and excited by the potential it may attribute to Immuron.”

Travelan’s active ingredient is Hyperimmune Bovine Colostrum Powder, a rich source of antibodies that bind to Enterotoxigenic *E. coli* in the gastrointestinal tract, preventing them from attaching to the intestinal wall, thereby neutralising their ability to cause Travelers’ Diarrhea and its associated symptoms.

Hyperimmune Colostrum is developed under Immuron’s proprietary technology to create high titers of antibodies to a range of *E. coli* bacteria that is present in normal colostrum in very small amounts.

-- END --

Company Contact:

Thomas Liquard
Chief Executive Officer
AUS Ph: +61 (0)3 9824 5254
thomasliquard@immuron.com

Immuron US Investor Relations:

Jon Cunningham
RedChip Companies, Inc.
US Ph: +1 (407) 644 4256, (ext. 107)
jon@redchip.com

About Immuron:

Immuron Ltd (ASX: IMC; OTCQB: IMROY) is a microbiome company focused on developing and commercializing oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of Travelers’ diarrhea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.

For more information visit: www.immuron.com

Forward-Looking Statements:

Certain statements made in this release are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.